Skip to main content
. 2022 Mar 17;13:1425. doi: 10.1038/s41467-022-29089-8

Fig. 4. FrCas9 is promising in anti-HPV18 treatments.

Fig. 4

a The target coverages of FrCas9 and SpCas9 in HPV18 genomes. b The sgRNA distribution densities for FrCas9 in HPV18 genomes. c The sgRNA distribution densities for SpCas9 in HPV18 genomes. d The 19 sites distribution in HPV18 genome for GUIDE-seq comparisons between FrCas9 and SpCas9. e The schematic illustration and GUIDE-seq results of SpCas9 and FrCas9 targeting URR, E6 and E7 genes. The reads number was normalized. f The GUIDE-seq normalized on-target reads of FrCas9 and SpCas9 in 19 sites. g The GUIDE-seq off-target counts of FrCas9 and SpCas9 in 19 sites. h The on-target vs. off-target ratios of FrCas9 and SpCas9 (N =19 sites, P = 0.0000267, two-sided paired Wilcox test, **** representing P < 0.0001). Box plots indicate median (middle line), 25th, 75th percentile (box) and 5th and 95th percentile (whiskers). The ratio is defined by GUIDE-seq on-target reads dividing total off-target reads. i The FrCas9 induced cell apoptosis in HPV18 positive HeLa cell line. Source data are provided with this paper.